Target intelligence / Profile preview

Coagulation Factors (excluding Fibrinogen, FVIII, vWF, FXIII) (Coagulation Factors (excl. I, VIII, vWF, XIII))

Target
Coagulation Factors (excl. I, VIII, vWF, XIII)
Molecular classification
Plasma proteins, Serine proteases, Zymogens, Cofactors
01

Overview

This entry represents a group of coagulation factors essential for blood clotting, excluding Fibrinogen (Factor I), Factor VIII, von Willebrand factor (vWF), and Factor XIII. These factors—II (prothrombin), V, VII, IX, X, XI, and XII—participate in the coagulation cascade, a series of enzymatic reactions leading to the formation of a stable blood clot. Deficiencies in these factors can lead to bleeding disorders, while their overactivation can contribute to thrombotic events. Many of these factors are serine proteases that activate downstream components in the cascade. Vitamin K is required for post-translational modification of Factors II, VII, IX, and X.

Other names
Prothrombin groupVitamin K-dependent clotting factors (II, VII, IX, X)Contact factors (XII, XI)Factors II, V, VII, IX, X, XI, XII
02

Mechanism of action

Various: Vitamin K antagonists inhibit post-translational modification of Factors II, VII, IX, and X. Heparin activates antithrombin, which inhibits several coagulation factors. DOACs directly inhibit specific factors like Factor Xa or Thrombin (Factor IIa).

03

Biological functions

Blood coagulationHemostasisThrombus formationActivation of coagulation cascadeSerine protease activityRegulation of blood clotting
04

Disease associations

Hemophilia (B, C)ThrombosisBleeding disordersCardiovascular diseaseVitamin K deficiency bleeding
05

Safety considerations

Bleeding risk (anticoagulant-related)Thrombotic risk (in deficiency states)Drug interactions (anticoagulants)Heparin-induced thrombocytopenia (HIT)
06

Interacting drugs

Warfarin

4 more in the full profile.

07

Biomarkers

Prothrombin Time (PT)Activated Partial Thromboplastin Time (aPTT)Factor activity assays (e.g., Factor IX activity)INR (International Normalized Ratio)

Beyond the preview

Go deeper on Coagulation Factors (excluding Fibrinogen, FVIII, vWF, FXIII) (Coagulation Factors (excl. I, VIII, vWF, XIII)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coagulation Factors (excluding Fibrinogen, FVIII, vWF, FXIII) (Coagulation Factors (excl. I, VIII, vWF, XIII)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call